Stevens-Johnson Syndrome (SJS) and Ocular Involvement
What Is Stevens-Johnson Syndrome
Stevens-Johnson syndrome is a rare but serious immune-mediated reaction that affects the skin and mucous membranes, including the delicate surfaces of the eyes. According to StatPearls (updated 2024), Stevens-Johnson syndrome is a rare but life-threatening mucocutaneous disorder occurring in an estimated 1 to 6 cases per million persons per year in the U.S., with ocular involvement reported in up to 84% of patients. SJS is classified as a type IV hypersensitivity reaction, meaning the immune system overreacts and attacks healthy tissue. The reaction typically begins with flu-like symptoms such as fever, sore throat, and fatigue before progressing to painful skin blistering and mucosal erosion. The eyes, mouth, and genital areas are most frequently affected because these surfaces are lined with vulnerable mucous membranes. SJS is considered a medical emergency that requires hospital-based care.
SJS and toxic epidermal necrolysis (TEN) exist on the same disease spectrum and differ primarily in the amount of body surface area involved. When skin detachment covers less than 10 percent of the body, the condition is classified as SJS. Detachment between 10 and 30 percent is called SJS-TEN overlap, while involvement greater than 30 percent is classified as TEN. TEN carries a higher mortality rate, but even milder SJS can cause significant and lasting eye damage.
Certain factors increase the likelihood of developing SJS. Individuals with a weakened immune system, those with HIV, and patients with a personal or family history of SJS face elevated risk. Genetic markers, particularly HLA-B*1502 in some populations, have been associated with a higher susceptibility to drug-triggered SJS. Most cases are triggered by medications, though infections such as Mycoplasma pneumoniae and herpes simplex virus can also be responsible.
How SJS Affects the Eyes
The eyes are one of the most commonly and severely affected organs in SJS. During an SJS episode, the immune system targets the conjunctiva and the cornea. Inflammation destroys goblet cells that produce the mucous layer of the tear film and can damage limbal stem cells that are responsible for regenerating the corneal surface. Without these stem cells, the cornea loses its ability to heal and maintain clarity over time.
In the acute phase, the conjunctiva becomes inflamed and may develop membrane-like deposits or raw, eroded areas. The eyelids can swell and stick to the eye surface, forming adhesions called symblepharon that restrict eye movement. Corneal epithelial defects may develop and leave the eye vulnerable to fungal corneal infections and other secondary complications. Prompt ophthalmologic evaluation during hospitalization is critical to limiting the severity of these changes.
Research shows that initiating eye treatment within the first four days of disease onset can significantly reduce long-term ocular damage. Early intervention with topical corticosteroids and amniotic membrane transplantation helps suppress inflammation and protect corneal stem cells. Patients who receive delayed eye care are more likely to develop chronic complications that are difficult to reverse.
Ocular Symptoms of Stevens-Johnson Syndrome
Eye symptoms can appear during the acute illness or develop gradually over weeks to months. Acute ocular symptoms often develop rapidly and may include severe eye redness, pain and swelling, excessive tearing or mucous discharge, sensitivity to light, a gritty or burning sensation in the eyes, blurred vision or difficulty keeping the eyes open, and formation of membrane-like tissue on the inner eyelids.
Many patients continue to experience eye problems long after the initial SJS episode resolves. Chronic symptoms often include persistent dryness due to tear gland damage, foreign body sensation, and fluctuating vision. Some patients notice their eyelashes growing inward, which can scratch and irritate the corneal surface. These ongoing symptoms reflect structural changes to the eyelid margins, conjunctiva, and tear-producing glands that occurred during the acute phase.
Certain symptoms may indicate worsening corneal damage or secondary infection and should prompt urgent evaluation. Increasing pain, a white spot on the cornea, sudden vision decline, or worsening redness may signal a corneal ulcer or advancing scarring. Patients with a history of SJS should not delay seeking care when new or worsening eye symptoms arise, as conditions such as Acanthamoeba keratitis can develop on a compromised ocular surface and progress quickly.
Medications That Most Commonly Trigger SJS
Medications are the leading cause of Stevens-Johnson syndrome. Antiepileptic drugs are among the most frequently implicated medications. Lamotrigine is the single most commonly reported trigger, followed by carbamazepine and phenytoin. These medications are widely prescribed for seizure disorders, bipolar disorder, and nerve pain. Patients starting any of these drugs should be counseled about the early warning signs of SJS, including fever, mouth sores, and skin tenderness.
Sulfonamide antibiotics, particularly trimethoprim-sulfamethoxazole, are the most common antibiotic triggers of SJS. Other antibiotics that have been associated with the condition include certain cephalosporins, fluoroquinolones, and penicillins. While the overall risk remains low, patients with a prior history of drug-related skin reactions should inform their prescribing physician before starting a new antibiotic.
Several additional drug classes have been linked to SJS. These include allopurinol used to treat gout and high uric acid levels, nonsteroidal anti-inflammatory drugs particularly oxicam-type agents such as piroxicam, nevirapine and other antiretroviral medications used in HIV treatment, and sulfasalazine used for inflammatory bowel disease and rheumatoid arthritis. The reaction usually begins within one to four weeks of starting a new medication. Once a causative drug has been identified, it must be permanently avoided.
Frequently Asked Questions
Treatment depends on whether the disease is in its acute or chronic phase. During the acute phase, intensive topical lubricants, corticosteroid eye drops, and amniotic membrane transplantation are used to reduce inflammation and promote surface healing. In the chronic phase, treatment focuses on managing dry eye with preservative-free artificial tears, punctal plugs to retain moisture, and addressing structural changes like eyelid scarring or inward-turning lashes. Severe cases may require mucosal membrane grafting or keratoprosthesis.
Yes, SJS can lead to permanent vision loss in severe cases. Corneal scarring, limbal stem cell deficiency, and chronic ocular surface inflammation can all progressively reduce visual acuity. However, the severity of long-term outcomes varies widely. Patients who receive early and aggressive ophthalmic treatment during the acute phase have a significantly better chance of preserving functional vision.
Chronic complications range from persistent dry eye and meibomian gland dysfunction to more serious conditions including symblepharon, corneal neovascularization, limbal stem cell failure, and complete conjunctivalization of the corneal surface. Eyelid malposition such as entropion and trichiasis can cause ongoing corneal abrasion. These complications often require a combination of medical and surgical management over many years.
Scleral contact lenses are large-diameter gas-permeable lenses that vault over the entire cornea and rest on the sclera. They create a fluid reservoir between the lens and the corneal surface, which continuously bathes the eye in saline and provides relief from dryness, irritation, and photophobia. For many SJS patients, scleral lenses significantly improve both comfort and visual acuity. Cornea specialists can evaluate whether scleral lenses are appropriate based on the extent of ocular surface changes and eyelid anatomy.
Any patient diagnosed with or suspected of having SJS should receive an ophthalmologic evaluation as soon as possible, ideally within the first few days of symptom onset. Even patients who do not initially show eye symptoms should be monitored, as ocular involvement can develop or worsen over the course of the illness. After the acute phase, ongoing follow-up is essential because chronic eye complications can emerge months or even years later.
The prognosis depends on the severity of the initial eye involvement and the timing of treatment. Studies show that best-corrected visual acuity improved in over 50 percent of eyes that received appropriate multimodal treatment. Mild cases may resolve with minimal long-term effects, while severe cases involving limbal stem cell loss or deep corneal scarring may require ongoing management. Patients with a history of herpes simplex keratitis or other corneal infections should be especially vigilant, as a compromised ocular surface is more susceptible to recurrent problems.
What our Patients say
4.8
Reviews
(3,408)